Ser326
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9.3
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Ser326  -  PLK1 (human)

Site Information
LTIPPRFsIAPssLD   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 5393500

In vivo Characterization
Methods used to characterize site in vivo:
immunoprecipitation ( 3 ) , mass spectrometry ( 1 , 2 ) , mutation of modification site ( 3 ) , phospho-antibody ( 3 ) , western blotting ( 3 )
Disease tissue studied:
melanoma skin cancer ( 1 )
Relevant cell line - cell type - tissue:

Upstream Regulation
Putative in vivo kinases:
MAPKAPK2 (human) ( 3 )
Kinases, in vitro:
MAPKAPK2 (human) ( 3 )
Treatments:
nocodazole ( 3 ) , seliciclib ( 3 ) , ZK-Thiazolidinone ( 2 )

Downstream Regulation
Effects of modification on PLK1:
enzymatic activity, induced ( 3 )
Effects of modification on biological processes:
cell cycle regulation ( 3 )

References 

1

Stuart SA, et al. (2015) A Phosphoproteomic Comparison of B-RAFV600E and MKK1/2 Inhibitors in Melanoma Cells. Mol Cell Proteomics 14, 1599-615
25850435   Curated Info

2

Santamaria A, et al. (2011) The Plk1-dependent phosphoproteome of the early mitotic spindle. Mol Cell Proteomics 10, M110.004457
20860994   Curated Info

3

Tang J, Yang X, Liu X (2008) Phosphorylation of Plk1 at Ser326 regulates its functions during mitotic progression. Oncogene 27, 6635-45
18695677   Curated Info